EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 3.0

Radiation therapy in a ductal carcinoma in situ patient with ornithine transcarbamylase deficiency: a case report

Iris Kang, Justin Park, Christine Yang, Aster Kim, Mary Tang, Kaye Lu, Azadeh Carr, Stephen F Sener, Rachel McGowan, Shoji Yano, Stella K Yoo

Radiation Oncology Journal · 31.12.2025 · 43 (4) · 214-219

DOI: 10.3857/roj.2025.00423 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Radiation Oncology Journal, erschienen am 31.12.2025. Verfasst von Iris Kang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ornithine transcarbamylase (OTC) deficiency is a rare urea cycle disorder that impairs ammonia detoxification, increasing the risk of hyperammonemic crises under metabolic stress. While chemotherapy-related risks have been reported, data on the safety of ionizing radiation therapy (RT) in this population are limited. This case describes a 30-year-old woman with late-onset OTC deficiency diagnosed with right-sided ductal carcinoma in situ. She underwent segmental mastectomy followed by adjuvant 3D conformal RT (40 Gy in 15 fractions with a concomitant boost to 48 Gy). Her multidisciplinary care involved preoperative hydration, close nutritional monitoring, and serial ammonia measurements. She completed RT without treatment interruptions or signs of hyperammonemia. This case illustrates that breast RT can be delivered safely in patients with OTC deficiency with a multidisciplinary, preventative approach. To our knowledge, this is the first report describing RT planning and metabolic surveillance in this population.

Schlagwörter

Stichwörter der Autor:innen

Breast neoplasmsCase reportsHyperammonemiaOrnithine carbamoyltransferase deficiency diseaseRadiotherapyUrea cycle disorders

Autor:innen und Institutionen

  • Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA.
  • Department of Radiation Oncology, Los Angeles General Medical Center, Los Angeles, CA, USA.
  • Department of Radiation Oncology, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA.
  • University of California, Los Angeles, Los Angeles, CA, USA.
  • Pepperdine University, Pepperdine, CA, USA.
  • Department of Surgery, Los Angeles General Medical Center, Los Angeles, CA, USA.

Zitieren

APA

Kang, I., Park, J., Yang, C., Kim, A., Tang, M., Lu, K., Carr, A., Sener, S. F., McGowan, R., Yano, S., & Yoo, S. K. (2025). Radiation therapy in a ductal carcinoma in situ patient with ornithine transcarbamylase deficiency: a case report. Radiation Oncology Journal, 43(4), 214-219. https://doi.org/10.3857/roj.2025.00423

Vancouver

Kang I, Park J, Yang C, Kim A, Tang M, Lu K, et al. Radiation therapy in a ductal carcinoma in situ patient with ornithine transcarbamylase deficiency: a case report. Radiation Oncology Journal. 2025;43(4):214-219. doi:10.3857/roj.2025.00423

BibTeX
@article{Kang2025,
  author = {Kang, Iris and Park, Justin and Yang, Christine and Kim, Aster and Tang, Mary and Lu, Kaye and Carr, Azadeh and Sener, Stephen F and McGowan, Rachel and Yano, Shoji and Yoo, Stella K},
  title = {Radiation therapy in a ductal carcinoma in situ patient with ornithine transcarbamylase deficiency: a case report},
  journal = {Radiation Oncology Journal},
  year = {2025},
  volume = {43},
  number = {4},
  pages = {214--219},
  doi = {10.3857/roj.2025.00423}
}
Kostenlos starten →